Technology evaluation: cT84.66, City of Hope

Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.

PPAR research·2008

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Radiation research·2007

Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Molecular biotechnology·2007

Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.

Anti-cancer drugs·2007

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.

BMC cancer·2007

Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).

Cancer research·2005

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study.

Frontiers in oncology·2026

Chitosan Nanoparticles for the Treatment of Ischemia-Reperfusion Injury: Mechanisms, Preclinical Evidence, Challenges, and Future Perspectives.

Journal of drug targeting·2026

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Human vaccines & immunotherapeutics·2026

CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.

Hematology (Amsterdam, Netherlands)·2026

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Asia-Pacific journal of clinical oncology·2026

Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study.

Medicine·2026

Related Experiment Videos

Technology evaluation: cT84.66, City of Hope

Related Concept Videos

Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.

Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).

Gene therapy: Have the risks associated with viral vectors been solved?

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study.

Chitosan Nanoparticles for the Treatment of Ischemia-Reperfusion Injury: Mechanisms, Preclinical Evidence, Challenges, and Future Perspectives.

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

CD7 CAR-T cells eliminate chronic myeloid leukemia stem cells specifically and effectively.

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study.

Related Experiment Videos

Technology evaluation: cT84.66, City of Hope

Abstract:

Related Concept Videos

Related Articles